MHA Hydrogel Microbeads for Controlled Subcutaneous Hormone Release

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing hormone therapies face challenges such as inconsistent dosage delivery, adverse effects, and poor patient compliance due to methods like pills, patches, and creams, while subcutaneous hydrogel formulations face absorption and bioavailability issues.

Innovation Solution

The use of crosslinked methacrylate hyaluronic acid (MHA) polymer microbeads encapsulating hormones, administered via a syringe, provides a controlled release of hormones into subcutaneous tissue, offering stable and extended hormone delivery.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If subcutaneously inserted slow-release hormone therapies (hydrogels or pellets) are used, then hormone delivery consistency and patient compliance improve, but absorption and bioavailability issues occur

Engineering Contradiction:

Improvehormone delivery consistencyVSAvoidhormone absorption and bioavailability

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent changes the physical-chemical parameters of the hydrogel formulation by using crosslinked methacrylate hyaluronic acid (MHA) polymer with specific molecular weight ranges (50-500 kDa) and controlling the degree of crosslinking. This optimization of polymer parameters improves both the consistency of hormone release and the bioavailability of testosterone, resolving the contradiction between reliable delivery and effective absorption

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a composite material system consisting of crosslinked MHA polymer network combined with testosterone hormone. The specific composite structure where testosterone is encapsulated within the crosslinked hydrogel matrix enables controlled release while maintaining high bioavailability, addressing both the reliability and absorption requirements

Inventive Principle:

Principle #40Composite materials

2Ease of operation

If traditional hormone therapies (pills, patches, creams) are used, then ease of administration is maintained, but dosage delivery consistency deteriorates

Engineering Contradiction:

Improveease of administrationVSAvoiddosage delivery consistency

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent replaces the mechanical delivery systems of pills (oral ingestion), patches (transdermal diffusion), and creams (topical application) with a subcutaneous injection system using crosslinked MHA hydrogel. This substitution provides mechanically controlled, consistent dosage delivery through the injection mechanism while maintaining patient convenience through extended-release properties lasting weeks to months

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If frequent hormone re-administration is performed, then hormone levels are maintained, but patient compliance and treatment burden worsen

Engineering Contradiction:

Improvehormone level maintenanceVSAvoidtreatment frequency and patient burden

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent achieves continuous hormone delivery through the crosslinked MHA hydrogel formulation that releases testosterone steadily over extended periods (weeks to months). This continuous release mechanism eliminates the need for frequent re-administration while maintaining stable hormone levels, significantly reducing patient burden and improving compliance

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The MHA polymer microbeads ensure consistent hormone release for up to two months, reducing the need for frequent re-administration and improving patient compliance and hormone balance.

Implementation Method 1

The method releases the hormone from the crosslinked MHA polymer into the subcutaneous tissue

Methodology Applied

Scientific EffectDiffusion: Diffusion

Implementation Method 2

The crosslinked polymer is generated by applying an ultraviolet light to a hydrogel precursor to initiate free radical photopolymerization

Methodology Applied

Scientific EffectPhotopolymerization: Photopolymerisation

Data Source

PatentUS20250319098A1Hormone replenishment method with a hydrogel polymer

Publication Date: 2025.10.16 VITALTE LIFESCIENCES INC

AI summary

A method of hormone replenishment with a hydrogel polymer that encapsulates a hormone. The method includes generating a crosslinked methacrylate hyaluronic acid (MHA) polymer that encapsulates a hormone. The crosslinked MHA polymer is the hydrogel polymer. The method proceeds by administering a dosage of the crosslinked MHA polymer that encapsulates the hormone to subcutaneous tissue with a syringe. The method continues by releasing the hormone from the crosslinked MHA polymer into the subcutaneous tissue.